POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 00010/0137.
Nimotop 30mg Tablets
Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end of the leaflet to establish if there have been any changes.
If you have any doubts or queries about your medication, please contact your doctor or pharmacist.
Package leaflet: Information for the user
Nimotop® 30 mg Tablets
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
1. What Nimotop tablets are and what they are used for
2. What you need to know before you take Nimotop tablets
3. How to take Nimotop tablets
4. Possible side effects
5. How to store Nimotop tablets
6. Contents of the pack and other information
1 What Nimotop tablets are and what they are used for
Nimotop tablets contains nimodipine, which belongs to a group of medicines called calcium antagonists.
Nimotop tablets are used to prevent changes in brain function after bleeding around the brain (subarachnoid haemorrhage).
2 What you need to know before you take Nimotop tablets
Do not take Nimotop tablets:
Warnings and precautions
Talk to your doctor or pharmacist before taking Nimotop tablets
Children and adolescents
Do not give Nimotop tablets to children under the age of 18 as the safety and efficacy of Nimotop have not been established.
Other medicines and Nimotop tablets
You will not be given Nimotop tablets if you are receiving Nimotop Solution.
You are not to be given rifampicin (an antibiotic), phenobarbital, phenytoin, or carbamazepine (anti-epileptic drugs) if you are taking Nimotop tablets.
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Some medicines may affect the way Nimotop tablets works. Tell your doctor if you are taking:
Nimotop tablets with food and drink
You can take Nimotop tablets with or without food.
Do not drink grapefruit juice or eat grapefruit while taking Nimotop tablets.
Do not start taking Nimotop tablets within 4 days of drinking grapefruit juice or eating grapefruit. Tell your doctor if you have had grapefruit or grapefruit juice in this time. Also, do not drink grapefruit juice or eat grapefruit whilst taking Nimotop tablets. Grapefruit juice is known to increase the blood levels of the active ingredient, nimodipine. This effect can last for at least four days.
Pregnancy, breast-feeding and fertility
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Follow his/her instructions carefully.
Do not breast-feed while taking Nimotop tablets.
If you are trying to father a child, talk to your doctor. Medicines like Nimotop tablets can sometimes affect male fertility.
Driving and using machines
Nimotop tablets may make you feel dizzy. Do not drive or operate machinery if you are affected in this way.
3 How to take Nimotop tablets
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Swallow the tablets with a little water.
Do not take more than your doctor has prescribed.
If you take more Nimotop tablets than you should
If you forget to take the tablets
Take your normal dose immediately and carry on taking that day’s tablets at 4-hour intervals.
Do not take a double dose to make up for the forgotten tablets.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4 Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Potentially serious side effects
If you experience:
Less serious side effects
In addition to the serious side effects listed above, these are the other less serious side effects of Nimotop tablets:
Uncommon side effects
(These may affect less than 1 in 100 people)
Rare side effects
(These may affect less than 1 in 1,000 people)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.
5 How to store Nimotop tablets
Keep this medicine out of the sight and reach of children.
Do not store above 30°C.
Do not use this medicine after the expiry date which is stated on both the outer carton and on each blister strip of tablets after EXP. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6 Contents of the pack and other information
What Nimotop tablets contain
The active substance is nimodipine. Each film-coated tablet contains 30 mg of nimodipine.
The other ingredients are microcrystalline cellulose, hypromellose, macrogol, maize starch, povidone, crospovidone, magnesium stearate and the colourings titanium dioxide (E171) and iron oxide yellow (E172).
What Nimotop tablets looks like and contents of the pack
The tablets come in boxes of 100, but your doctor will prescribe as many as you need.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation holder:
This leaflet was last revised in August 2017.
Product Licence Number: PL 00010/0137